GV1001 Peptide Rescues Neurodegeneration in Alzheimer Mouse Model
This study explores GV1001, a peptide initially developed for cancer, which has shown promise in AD treatment. Researchers used the 5xFAD mouse model to investigate the effects of GV1001.
GV1001 is a peptide consisting of 16 amino acids derived from the catalytic subunit of human telomerase reverse transcriptase. A recent phase II clinical trial in patients with Alzheimer disease (AD) showed that GV1001 effectively improved memory impairment with proven safety, leading to larger clinical trials. However, the mechanisms underlying therapeutic effects of GV1001 on AD remain elusive.
Researchers used the 5xFAD mouse model to investigate the effects of GV1001. This approach allows for the study of amyloid pathology in a controlled environment relevant to human disease progression. The findings provide mechanistic insight into how this peptide influences microglial behavior and plaque clearance.
The main findings indicate that GV1001 reduces amyloid plaque burden and rescues synaptic loss and memory deficits in 5xFAD mice by increasing microglial migration toward large amyloid plaques and amyloid β degradation. Single-cell RNA-sequencing revealed that GV1001 promoted the migratory and phagocytic phenotypes by modulating disease-associated microglial profiles.
At the molecular level, through virtual target screening and docking simulation combined with peptide pulldown, researchers identified that bradykinin receptor 1 is the binding target of GV1001. Furthermore, they revealed that GV1001 facilitated microglial migration and amyloid β phagocytosis in an mTORC2-dependent manner.
Collectively, the authors' work demonstrates the amyloidolytic effects and the relevant in-depth signaling mechanism of GV1001 in microglia. This research suggests GV1001 as a promising disease-modifying therapeutic agent for AD. These findings highlight potential targets for future peptide-based interventions in neurodegenerative research.